Bruce D. Cheson

Professor of Medicine
Hematology / Oncology
Georgetown University, USA

Recent publications

Cheson BD, Horwitz SM, Weisenburger DD.
Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii.
Clin Adv Hematol Oncol., 9 (11 Suppl 26): 1-14; quiz 15- 6 (2011)

Koprivnikar JL, Cheson BD.
Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin’s lymphoma.
Future Oncol., 8 (4):359-71 (2012)

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma.
J Clin Oncol., 30 (18): 2183-9. Epub 2012 Mar 26 (2012)

Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Ann Oncol., 23 (9): 2356-62. Epub 2012 Feb 22 (2012)

Vose JM, Friedberg JW, Waller EK, Cheson BD, Juvvigunta V, Fritsch H, Petit C, Munzert G, Younes A.
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin’s lymphoma: A Phase I, open-label, single dose-escalation study.
Leuk Lymphoma., [Epub ahead of print] (2012)

Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S.
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.
Cancer., 118 (12): 3128-34 (2012)